In this study, it was aimed to investigate the possible protective effects of gilaburu (Viburnum opulus L., Glb) fruit extract on testis and sperm damages induced by docetaxel (DTX) and paclitaxel (PTX) chemotherapeutics in rats. Sixty adult male Wistar albino rats were divided into 6 equal groups, 10 animals each. The groups were created as control (weekly i.p. saline injection), Glb (weekly i.p. saline injection and daily oral 100mg/kg Glb), DTX (weekly i.p. injection of 5mg/kg DTX), PTX (weekly i.p. injection of 4mg/kg PTX), DTX+Glb (weekly i.p. injection of 5mg/kg DTX and daily oral 100mg/kg Glb) and PTX+Glb (weekly i.p. injection of 4mg/kg PTX and daily oral 100mg/kg Glb). Following 10-week chronic application, spermatological, biochemical, histopathological, cytopathological and immunohistochemical examinations were performed. DTX and PTX caused significant decreases in absolute and relative weights of all reproductive organs, testosterone level, sperm motility, concentration, Bcl-2 anti-apoptotic immunopositive cell scores of testes and spermatozoa as well as catalase activity in epididymal tissue, superoxide dismutase and glutathione peroxidase activities of testicular and epididymal tissues when compared with the control group. Both drugs also significantly increased abnormal sperm rate, testicular and epididymal malondialdehyde level, Bax pro-apoptotic immunopositive cell scores of testes and spermatozoa, and caused remarkable testicular histological and cytological damages. However, Glb consumption mitigated the PTX-induced decreases in absolute weights of epididimis, seminal vesicles, ventral prostate and both taxanes-induced disturbances in sperm characteristics, imbalances in oxidant/antioxidant system, increments in germ cell apoptosis and testicular histo-and cyto-pathological damages. It was concluded that long-term Glb consumption alleviates the taxanes-induced damages in reproductive system of male rats.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biopha.2017.09.057 | DOI Listing |
PLoS One
January 2025
French National Reference Center for Primary Immunodeficiencies (CEREDIH) and Pediatric Immunology, Hematology and Rheumatology Unit, Necker Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.
Background: Subcutaneous immunoglobulin (SCIg) replacement therapy is indicated for patients with hypogammaglobulinemia caused by primary (PID) and secondary immunodeficiencies (SID).
Objective: To compare healthcare resource utilization (HCRU) and related direct medical costs of patients in France treated with weekly conventional SCIg (cSCIg) vs monthly hyaluronidase-facilitated SCIg (fSCIg).
Methods: This retrospective study of Ig-naïve patients with PID or SID newly receiving a SCIg between 2016 and 2018, extracted from the French National Healthcare reimbursement database (SNDS), analyzed the SCIg-related HCRU and reimbursed costs generated from in-hospital (hospitalizations and SCIg doses) or at-home (nurse visits [NV] and pump provider visits [PPV], drug doses) SCIg administration.
Curr Stem Cell Res Ther
January 2025
Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, P.O. Box 62521, Beni-Suef, Egypt.
Introduction: Osteoarthritis (OA) is a degenerative joint disease that can affect the many tissues of the joint. There are no officially recognized disease-modifying therapies for clinical use at this time probably due to a lack of complete comprehension of the pathogenesis of the disease. In recent years, emerging regenerative therapy and treatments with stem cells both undifferentiated and differentiated cells have gained much attention as they can efficiently promote tissue repair and regeneration.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
Aims: Evaluate glycated haemoglobin (HbA1c) and weight changes after 6 months of once-weekly (QW) injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in UK primary care.
Materials And Methods: Retrospective, non-interventional study, using the Clinical Practice Research Datalink Aurum primary care database, identified adults with type 2 diabetes (T2D) newly initiating a QW injectable GLP-1 RA between January 2020 and November 2021. Dual primary outcomes were proportion of patients with (1) HbA1c < 7% (<53 mmol/mol) and (2) weight loss categories (from 0% to 15+%) after 6 months of continuous GLP-1 RA therapy.
Front Cell Neurosci
January 2025
Laboratório de Neurodegeneração e Reparo - Departamento de Anatomia Patológica, Hospital Universitário Clementino Fraga Filho, HUCFF/UFRJ, Rio de Janeiro, Brazil.
Background: Following transection, nerve repair using the polylactic acid (PLA) conduit is an effective option. In addition, inosine treatment has shown potential to promote nerve regeneration. Therefore, this study aimed to investigate the regenerative potential of inosine after nerve transection and polylactic acid conduit repair.
View Article and Find Full Text PDFCMAJ
January 2025
Department of Medicine (Shin, Yu), St. Michael's Hospital, University of Toronto, Toronto, Ont.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!